


**AMENDED CLAIM SET:**

1. (cancelled).

2. (previously presented) A 1,2,4-benzothiadiazine derivative of the formula:



wherein

R<sup>3</sup> represents cycloalkyl; and

R<sup>4</sup> represents hydrogen; and

R<sup>5</sup> represents hydrogen; and

R<sup>6</sup> represents hydrogen or alkyl; and

R<sup>7</sup> represents -SO<sub>2</sub>-NR<sup>17</sup>R<sup>18</sup>, wherein R<sup>17</sup> and R<sup>18</sup> independently of each another represent hydrogen or alkyl, or R<sup>17</sup> and R<sup>18</sup> together with the nitrogen to which they are attached form a heterocyclic 3- to 8-membered ring structure, which ring structure is optionally substituted with alkyl; and

R<sup>8</sup> represents hydrogen or alkyl.

3. – 7. (cancelled).

8. (previously presented) The 1,2,4-benzothiadiazine derivative of claim 2, wherein R<sup>7</sup> represents -SO<sub>2</sub>-NR<sup>17</sup>R<sup>18</sup>, wherein R<sup>17</sup> and R<sup>18</sup> independently represent hydrogen or alkyl.

9. (cancelled).

10. (currently amended) The 1,2,4-benzothiadiazine derivative of claim 2, wherein

R<sup>3</sup> represents cycloalkyl; and  
R<sup>4</sup> represents H; and  
R<sup>5</sup> represents H; and  
R<sup>6</sup> represents hydrogen or alkyl; and  
R<sup>7</sup> represents -SO<sub>2</sub>-NR<sup>17</sup>R<sup>18</sup>, wherein R<sup>17</sup> and R<sup>18</sup> independently represent hydrogen or alkyl, or R<sup>17</sup> and R<sup>18</sup> together with the nitrogen to which they are attached form a heterocyclic 3- to 8-membered ring structure, which ring structure is optionally substituted with alkyl; and  
R<sup>8</sup> represents alkyl.

11. (previously presented) The 1,2,4-benzothiadiazine derivative of claim 2, wherein R<sup>3</sup> represents cyclopentyl or cyclohexyl.

12. (cancelled).

13. (cancelled).

14. (previously presented) The 1,2,4-benzothiadiazine derivative of claim 2, wherein R<sup>6</sup> represents hydrogen or methyl.

15. (previously presented) The 1,2,4-benzothiadiazine derivative of claim 2, wherein R<sup>7</sup> represents N,N-dimethylsulfamoyl, N,N-diethylsulfamoyl, or -SO<sub>2</sub>-heterocyclic ring, wherein the heterocyclic ring is selected from the group of piperidine, pyrrolidine, 1,2,5,6-tetrahydropyridine, N-methylpiperazine, N-sulfonylmethyl-piperazine, and morpholine.

16. (cancelled).

17. (cancelled).

18. (withdrawn – currently amended) The 1,2,4-benzothiadiazine derivative of claim 2, wherein

R<sup>3</sup> represents cyclohexyl; and  
R<sup>7</sup> represents N,N-dimethylsulfamoyl; and  
R<sup>5</sup>, R<sup>4</sup>, R<sup>6</sup>, and R<sup>8</sup> all represent hydrogen.

19. – 21. (cancelled).

22. (currently amended) The 1,2,4-benzothiadiazine derivative according to claim 2, said compound being:

3-Cyclohexyl-7-(*N,N*-diethylamino)sulfonyl-1,2,3,4-tetrahydro-1,2,4-benzothiadiazine-1,1-dioxide;

3-Cyclohexyl-7-pyrrolidinosulfonyl-1,2,3,4-tetrahydro-1,2,4-benzothiadiazine-1,1-dioxide;

3-Cyclopropyl-7-piperidinosulfonyl-1,2,3,4-tetrahydro-1,2,4-benzothiadiazine-1,1-dioxide;

3-Cyclopentyl-7-piperidinosulfonyl-1,2,3,4-tetrahydro-1,2,4-benzothiadiazine-1,1-dioxide;

3-Cyclohexyl-7-piperidinosulfonyl-1,2,3,4-tetrahydro-1,2,4-benzothiadiazine-1,1-dioxide;

3-Cyclohexyl-7-(1',2',3',6'-tetrahydropiperidino)sulfonyl-1,2,3,4-tetrahydro-1,2,4-benzothiadiazine-1,1-dioxide;

3-Cyclohexyl-7-(4'-methylpiperazino)sulfonyl-1,2,3,4-tetrahydro-1,2,4-benzothiadiazine-1,1-dioxide;

3-Cyclohexyl-7-(4'-methylsulfonylpiperazino)sulfonyl-1,2,3,4-tetrahydro-1,2,4-benzothiadiazine-1,1-dioxide;

3-Cyclohexyl-7-morpholinosulfonyl-1,2,3,4-tetrahydro-1,2,4-benzothiadiazine-1,1-dioxide;

~~3-Cyclohexyl-8-methoxy-1,2,3,4-tetrahydro-1,2,4-benzothiadiazine-1,1-dioxide;~~

3-Cyclopentyl-6-methyl-7-piperidinosulfonyl-1,2,3,4-tetrahydro-1,2,4-benzothia-diazine-1,1-dioxide;

3-Cyclohexyl-6-methyl-7-morpholinosulfonyl-1,2,3,4-tetrahydro-1,2,4-benzothiadiazine-1,1-dioxide; or

3-Cyclohexyl-7-sulfamoyl-1,2,3,4-tetrahydro-1,2,4-benzothiadiazine-1,1-dioxide;

or a pharmaceutical acceptable salt thereof.

23. (cancelled).

24. (previously presented) A pharmaceutical composition comprising an effective amount of a 1,2,4-benzothiadiazine derivative according to claim 2, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable excipient, carrier or diluent.

25. – 27. (cancelled).

28. (withdrawn - currently amended) A method of treating a disorder or disease of a living animal body, including a human, which disorder or disease is responsive to modulation of the AMPA receptor complex of the central nervous system wherein the disorder or disease is selected from psychotic disorders, sexual dysfunction, intellectual impairment disorders, and depression, which method comprises administration of a therapeutically effective amount of a 1,2,4-benzothiadiazine derivative according to claim 2.

29. (cancelled).

30. (cancelled).

31. (cancelled).

32. (cancelled).

33. (previously presented) The 1,2,4-benzothiadiazine derivative of claim 22, which is 3-cyclopentyl-6-methyl-7-piperidinosulfonyl-1,2,3,4-tetrahydro-1,2,4-benzothiadiazine-1,1-dioxide; or a pharmaceutically acceptable salt thereof.